Molecular characterization of a voriconazole-resistant, posaconazole-susceptible Aspergillus fumigatus isolate in a lung transplant recipient in the United States

Jose Antonio Vazquez, Elias Kurian Manavathu

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Molecular characterization of cyp51A from the azole-resistant Aspergillus fumigatus isolate 50593 from a lung transplant patient showed Y121F/T289A changes coupled with a 46-bp tandem repeat (TR46) on the promoter, whereas cyp51A from the pretherapy isolate, A. fumigatus 47381, showed no changes. This is the first reported case of A. fumigatus azole resistance due to Y121F/T289A/TR46 in the United States, suggesting that multiple mutational alterations of cyp51A resulting in high-level azole resistance could occur during prolonged antifungal therapy.

Original languageEnglish (US)
Pages (from-to)1129-1133
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Azoles
Aspergillus fumigatus
Lung
Tandem Repeat Sequences
Transplants
posaconazole
Voriconazole
Transplant Recipients
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

@article{c28d758c445a4270877cc87094f7a99e,
title = "Molecular characterization of a voriconazole-resistant, posaconazole-susceptible Aspergillus fumigatus isolate in a lung transplant recipient in the United States",
abstract = "Molecular characterization of cyp51A from the azole-resistant Aspergillus fumigatus isolate 50593 from a lung transplant patient showed Y121F/T289A changes coupled with a 46-bp tandem repeat (TR46) on the promoter, whereas cyp51A from the pretherapy isolate, A. fumigatus 47381, showed no changes. This is the first reported case of A. fumigatus azole resistance due to Y121F/T289A/TR46 in the United States, suggesting that multiple mutational alterations of cyp51A resulting in high-level azole resistance could occur during prolonged antifungal therapy.",
author = "Vazquez, {Jose Antonio} and Manavathu, {Elias Kurian}",
year = "2016",
month = "2",
day = "1",
doi = "10.1128/AAC.01130-15",
language = "English (US)",
volume = "60",
pages = "1129--1133",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Molecular characterization of a voriconazole-resistant, posaconazole-susceptible Aspergillus fumigatus isolate in a lung transplant recipient in the United States

AU - Vazquez, Jose Antonio

AU - Manavathu, Elias Kurian

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Molecular characterization of cyp51A from the azole-resistant Aspergillus fumigatus isolate 50593 from a lung transplant patient showed Y121F/T289A changes coupled with a 46-bp tandem repeat (TR46) on the promoter, whereas cyp51A from the pretherapy isolate, A. fumigatus 47381, showed no changes. This is the first reported case of A. fumigatus azole resistance due to Y121F/T289A/TR46 in the United States, suggesting that multiple mutational alterations of cyp51A resulting in high-level azole resistance could occur during prolonged antifungal therapy.

AB - Molecular characterization of cyp51A from the azole-resistant Aspergillus fumigatus isolate 50593 from a lung transplant patient showed Y121F/T289A changes coupled with a 46-bp tandem repeat (TR46) on the promoter, whereas cyp51A from the pretherapy isolate, A. fumigatus 47381, showed no changes. This is the first reported case of A. fumigatus azole resistance due to Y121F/T289A/TR46 in the United States, suggesting that multiple mutational alterations of cyp51A resulting in high-level azole resistance could occur during prolonged antifungal therapy.

UR - http://www.scopus.com/inward/record.url?scp=84957900240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957900240&partnerID=8YFLogxK

U2 - 10.1128/AAC.01130-15

DO - 10.1128/AAC.01130-15

M3 - Article

C2 - 26574014

AN - SCOPUS:84957900240

VL - 60

SP - 1129

EP - 1133

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -